Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data, Analytics & AI · Posttraumatic stress disorder (PTSD)-related intervention trials

Designing Intervention Trials for Posttraumatic Stress Disorder: Outcomes, Comparators and Attrition

A posttraumatic stress disorder (PTSD) trial shares every design challenge of a psychiatric intervention trial and faces one additional, unavoidable challenge: defining a credible comparator for a condition partly defined by the need to feel safe.

Pubrica AcademyWritten by a clinical-trials reviewer Reviewed bya biostatistician Published10 October 2026 Last checked10 October 2026 Reading time9 minutes Sources1 peer-reviewed

A posttraumatic stress disorder (PTSD) intervention trial evaluates a psychological, pharmacological or combined treatment against a defined comparator in people meeting diagnostic criteria for PTSD, and carries specific methodological demands around outcome measurement, comparator choice, and attrition that a general-purpose trial design does not automatically resolve.

Learning objectives

  • Why standardised, clinician-administered outcome measurement matters particularly for PTSD trials.
  • The comparator-choice problem specific to trauma-focused psychological interventions.
  • Why attrition and its handling deserve particular attention in this population.
  • What established clinical practice guidelines expect a PTSD evidence base to look like.

Common misconceptions

  • “Self-report symptom scales are sufficient as a PTSD trial's primary outcome.” Clinical practice guideline development for PTSD treatment has relied heavily on clinician-administered structured interviews as a primary outcome standard, precisely because self-report alone can be more susceptible to expectation and reporting biases in this population.
  • “A waitlist control is an adequate comparator for any PTSD psychotherapy trial.” A waitlist comparator controls for the passage of time but not for nonspecific therapeutic contact, which is why active comparators (such as a credible alternative intervention) are preferred where feasible for isolating a specific trauma-focused intervention's effect.

Outcome measurement and the role of clinician-administered instruments

The American Psychological Association's Clinical Practice Guideline for the Treatment of PTSD in Adults, developed through a systematic review of the treatment evidence base, relies on structured, standardised symptom measurement as the basis for its treatment recommendations, reflecting the broader methodological expectation in this field that a primary outcome should be assessed with a validated, ideally clinician-administered, instrument rather than an unstandardised or purely self-report measure alone1. The rationale is that PTSD symptom reporting can be influenced by treatment expectation and by the social and clinical context of assessment, which a standardised, structured interview is designed to constrain more consistently than an open self-report format.

Selection of the comparator

Choosing a comparator for a trauma-focused psychological intervention trial is more complex than it may appear. A waitlist comparator (no active treatment during the trial period) controls for the simple passage of time, but it does not control for the nonspecific effects of regular supportive contact with a clinician, which many trauma-focused interventions provide independent of their specific technique. The APA guideline’s evidence synthesis reflects this methodological tension directly, by weighing trials against each other partly on the basis of the type of comparator used, since a trial against waitlist and a trial against an active comparator answer different questions about efficacy1.

Attrition in trauma-focused trials

Trauma-focused interventions, particularly those involving exposure to traumatic memories, can be experienced as aversive by some participants, which creates a specific pattern of attrition risk that should be anticipated in trial design: participants who find the intervention most difficult may also be most likely to drop out, which is precisely the missing-not-at-random pattern that biases a trial’s effect estimate if not planned for. This is the same missing-data principle covered generally in our piece on missing data in clinical trials, applied to a population and intervention type where the risk is particularly plausible rather than hypothetical.

Key points

Key points

A PTSD intervention trial requires standardised, ideally clinician-administered outcome measurement; a comparator choice that is explicit about which nonspecific effects it does and does not control for; and a missing-data plan that anticipates attrition related to how aversive participants find the intervention itself.

Practical application

Practical application

  1. A clinician-administered primary outcome should be selected where feasible. A standardised, structured interview-based measure should be preferred to an unstandardised self-report instrument as the primary outcome, consistent with the evidence base on which clinical practice guidelines have relied.
  2. The comparator should be chosen and justified explicitly. The protocol should state whether the comparator is waitlist, treatment as usual or an active alternative intervention, and what that choice does and does not permit the trial to conclude about specific efficacy.
  3. Attrition related to the aversiveness of the intervention should be anticipated. A missing-data analysis plan consistent with current missing-data guidance should be developed that explicitly considers whether dropout is related to participants’ experience of the intervention.

Frequently asked questions

It can be, particularly in early-phase or feasibility work, but its limitation (not controlling for nonspecific therapeutic contact) should be stated explicitly when interpreting the result.

Because some participants may find the intervention itself aversive, there is a plausible link between a participant’s response to treatment and the likelihood of dropout, which is the pattern that most biases a trial’s effect estimate.

Some challenges overlap (outcome measurement, attrition), but blinding and placebo comparator design differ substantially between pharmacological trials and psychotherapy trials, where a credible inert comparator is harder to construct.

References

  1. American Psychological Association. Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults. 2017. read 10 October 2026. View APA PTSD Clinical Practice Guideline

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). Designing Intervention Trials for Posttraumatic Stress Disorder: Outcomes, Comparators and Attrition. Pubrica. https://pubrica.com/academy/concepts-definitions/posttraumatic-stress-disorder-ptsd-related-intervention-trials/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

PTSD trial design checklist stub

Use when designing a PTSD intervention trial.

[ ] Primary outcome: standardised, clinician-administered measure named
[ ] Comparator type stated and justified (waitlist / treatment-as-usual / active)
[ ] Nonspecific-effects limitation of comparator discussed
[ ] Missing-data plan addresses intervention-related attrition risk
[ ] Blinding/rater-independence approach stated

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s clinical-trials team designs outcome measurement, comparator strategies and missing-data plans for PTSD and other trauma-focused intervention trials to a standard that withstands methodological review.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Robust comparator and outcome selection for PTSD intervention trials

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.